Mezigdomide clinical trials
Mezigdomide is named as an intervention in 12 current clinical trials in our USA, Canada, Spain, UK, Israel, Germany, Norway, China, France, Italy, Japan, South Korea, Australia, India, Austria, Czechia, Brazil, Denmark, Singapore, Ireland, Belgium, Poland, Portugal, Turkey, Netherlands and Taiwan registers. 9 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is Celgene (3). The most-studied condition is Multiple Myeloma. The EU clinical trials register (CTIS) separately lists 3 authorised or ongoing trials.
How Mezigdomide works
All drug targets →- Plasma cell myelomaPhase 3
- Acute leukemiaPhase 1/2
- Acute myeloid leukemiaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4648616, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 12718, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Mezigdomide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Mezigdomide
12 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Mezigdomide in the EU trials register (CTIS)
3 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Mezigdomide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2026-526352-31-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Fundacion PETHEMA | Spain |
|
A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI)
2025-520976-25-00 · CTIS ↗ · Hemic and Lymphatic Diseases
|
Phase 2 | Authorised | Centre Hospitalier Universitaire De Saint Etienne | France |
|
A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)
2025-521090-14-00 · CTIS ↗ · Hemic and Lymphatic Diseases
|
Phase 2 | Authorised | Assistance Publique Hopitaux De Paris | France |
Conditions studied with Mezigdomide
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Celgene | 3 |
| Bristol-Myers Squibb | 2 |
| AbbVie | 1 |
| Karyopharm Therapeutics Inc | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| K36 Therapeutics, Inc | 1 |
| PETHEMA Foundation | 1 |
| YOUNGIL KOH | 1 |
| Massachusetts General Hospital | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Mezigdomide trials
How many clinical trials are testing Mezigdomide?
12 current trials in our USA, Canada, Spain, UK, Israel, Germany, Norway, China, France, Italy, Japan, South Korea, Australia, India, Austria, Czechia, Brazil, Denmark, Singapore, Ireland, Belgium, Poland, Portugal, Turkey, Netherlands and Taiwan registers name Mezigdomide (also registered as BMS-986348) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Mezigdomide trials recruiting patients?
Yes. 9 of the 12 trials are recruiting: 7 with sites in USA, 6 with sites in Canada, 4 with sites in Spain, 4 with sites in UK, 4 with sites in Israel, 2 with sites in Germany, 3 with sites in Norway, 2 with sites in China, 2 with sites in France, 1 with sites in Italy, 2 with sites in Japan, 2 with sites in South Korea, 2 with sites in Australia, 1 with sites in India, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Brazil, 1 with sites in Singapore, 1 with sites in Ireland, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in Portugal and 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Mezigdomide clinical trials?
Celgene (3), Bristol-Myers Squibb (2), AbbVie (1) and Karyopharm Therapeutics Inc (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Mezigdomide clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mezigdomide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mezigdomide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mezigdomide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.